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Abstract
An epidemic of pediatric obesity has occurred across the world in recent years. There are subgroups within the
population at high-risk of becoming obese and especially of having experience of precocious cardiovascular and
metabolic co-morbidities of obesity. One of these subgroups comprises patients treated for childhood cancers and
namely survivors of craniopharyngioma. The high incidence of obesity in this group makes these patients an
important disease model to better understand the metabolic disturbances and the mechanisms of weight gain
among cancer survivors. The hypothalamic-pituitary axis damage secondary to cancer therapies or to primary
tumor location affect long-term outcomes. Nevertheless, the aetiology of obesity in craniopharyngioma is not yet
fully understood. The present review has the aim of summarizing the published data and examining the most
accepted mechanisms and main predisposing factors related to weight gain in this particular population.
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Introduction
As results of advances in treatment, almost 80% of chil-
dren and adolescents who receive a diagnosis of cancer
become long-term survivors. In the United States, there
are approximately 270.000 survivors of pediatric cancer
reaching the amount of about 1 every 640 adults
between the ages of 20 and 39 years [1]. The improved
survival rates have resulted in increased attention on
late side-effects. They can include second malignancies,
cardiovascular abnormalities, pulmonary complications,
endocrine consequences and obesity. In the Childhood
Cancer Survivor Study, the survivor population is con-
sidered a high-risk population. Thirty years after a diag-
nosis of cancer, almost three fourths of survivors have a
chronic health condition, more than 40% have a serious
health problem and one third have multiple conditions
[2]. Some of these adverse health effects may be modifi-
able and, therefore, the long-term monitoring of survi-
vors has became an important part of their overall
health care and the identification of treatment and
patient factors that contribute to them is now crucial.
Obesity is a well-recognized complication of tumors
localized in the hypothalamic-pituitary region. In child-
hood, craniopharyngioma is the most common neo-
plasm of the hypothalamic-pituitary area, accounting for
approximately 80% of tumors in this location and repre-
sents 5-15% of intracranial tumors [3]. A Childhood
Cancer Registry estimates an incidence of craniopharyn-
gioma of 1.4 cases per million children per year in Italy
[4]. Similar data are provided by other registries in Wes-
tern countries, while higher rates have been observed in
Asia and Africa. Craniopharyngioma has a bimodal age
distribution with a peak between 5 and 14 years of age,
and a second one in adults older than 65 years. Even if
it is not truly malignant, it is locally invasive and grows
slowly in the suprasellar region. During its growth, cra-
niopharyngioma could invade surrounding tissue includ-
ing the hypothalamus and optic chiasm. Consequently,
even if survival has dramatically improved in the last
years (overall 10-years survival rate: 91-98%), this attach-
ment makes the complete excision of the tumor difficult
and the affected children may be visually impaired and
often develop multiple endocrine deficiencies [5]. Man-
agement of craniopharyngioma is therefore still complex
and controversial. Aiming the preservation of the
hypothalamic function, a complete resection of the
tumor is the treatment of choice only in patients with
favorable localization. When the tumor localization is
unfavorable, a limited resection followed by local irra-
diation is recommended [6].
In brain tumors, the location of the primary tumors
might be one of the principal factors affecting body
weight and composition. The hypothalamic obesity is
defined as a rapid, unrelenting and intractable weight
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associated with others symptoms, including headache,
impaired vision, increased somnolence and behavioral
disturbances, especially severe hyperphagia and abnor-
mal food seeking behaviors [7].
Hypothalamic involvement can derive by infiltration of
the tumor itself. In such cases, weight gain could be a
sign of the disease leading, together with other symp-
toms, to the diagnosis of craniopharyngioma. In a large
study of 63 children, 17% had a history of significant
weight gain in the 3.5 years before the diagnosis of cra-
niopharyngioma [8].
After tumor resection, survivors of childhood cranio-
pharingioma experienced an about 50% increased rate of
obesity [9-11]. In a study conducted in the St. Jude Chil-
dren’s Research Hospital, 65% of 55 patients treated for
craniopharyngioma during childhood (about 90% sur-
gery plus radiotherapy) were found overweight or obese
after 7.6 years (range 5-21.3 years) from diagnosis [12].
Muller showed that the extension of the tumor to the
hypothalamus was found in 76% of obese and 96% of
severely obese patients compared to 33% of normal
weight survivors [13]. Following surgery, mean Body-
Mass Index (BMI) Standard Deviation Score (SDS)
i n c r e a s e df r o m0 . 0t o2 . 7a t6m o n t h sa n dt o2 . 4a t1
year [8]. The increase of BMI correlates with the sever-
ity of hypothalamic damage evaluated both on preopera-
tive [9,14] and postoperative imaging [15,16].
In craniopharyngioma, a distinctive pattern of weight
gain has already emerged. Children who developed
hypothalamic obesity have a significant and rapid BMI
increase over the first 6 months after treatment, fol-
lowed by stabilization, with no subsequent loss of weight
[15]. That is the reason why an early and rapid post-
operative weight gain seems to be a significant predic-
tive factor for severe long-term obesity [10,17]. In
addition, patients who remained at normal weight dur-
ing follow-up after diagnosis of childhood craniopharyn-
gioma presented a lower BMI SDS at the time of the
diagnosis [9,10]. Therefore, an increased BMI at diagno-
sis of craniopharyngioma is reported as another signifi-
cant risk factor predictive of the development of severe
obesity [18,19]. It could derived from the presence of a
hypothalamic dysfunction prior the diagnosis of cranio-
pharyngioma, but it could also prove the presence of an
unhealthy lifestyle, already existing independently of the
subsequent diagnosis of craniopharyngioma.
Etiology of obesity in Craniopharyngioma
Alteration of the hypothalamic signal pathway
In craniopharyngioma weight gain can principally occur
from the disruption of the normal homeostatic function
of the hypothalamic centers responsible for controlling
satiety and hunger and regulating energy balance.
In physiological conditions, the hypothalamic arcuate
nucleus (ARC), located in median eminence, where
brain barrier is freely permeable, senses nutrient and
hormonal signals from the periphery and is the primary
site of two sets of neurons that form part of the central
melanocortin system, a key regulator of energy balance.
These two neuronal populations express both anorectic
[proopiomelanocortin (POMC)-product alpha-melano-
cyte-stimulating hormone (a-MSH)] and orexigenic
[agouti-related protein and neuropeptide Y (AGRP/
NPY)] peptides. Both leptin, an adipose tissue-related
cytokine, and insulin stimulate arcuate expression of
POMC and suppress AGRP/MPY expression [20,21].
Disruption of responses to leptin and insulin from
hypothalamic damage has been proposed as a possible
mechanism contributing to hypothalamic obesity [7]. A
disturbed feedback mechanism from the hypothalamic
leptin receptors to the adipose tissue can be assumed,
including a loss of leptin feedback inhibition on neuro-
peptide Y and appetite. Roth, evaluating serum leptin
levels in 14 patients after neurosurgical treatment for
craniopharyngioma, suggested that the hypothalamic
structures might be insensitive to endogenous leptin.
Normal controls had a positive correlation between lep-
tin levels and BMI. Significantly elevated leptin levels
with respect to BMI were found in 11 craniopharyn-
gioma patients who had been affected by a suprasellar
tumour, whereas 3 patients with an intrasellar tumor
had lower, almost normal serum leptin levels [22]. It has
been also showed leptin concentrations in serum of
patients with craniopharyngioma increased over propor-
tionally when patients developed obesity [23].
Animal studies suggest that hypothalamic obesity can
also result from increased parasympathetic and
decreased sympathetic activity [24]. In humans, an auto-
nomic imbalance has been already confirmed [25].
Patients with a history of hypothalamic craniopharyn-
gioma resection and high BMI values had an impaired
counter regulatory response to hypoglycemia with signif-
icantly lower levels of plasma epinephrine [26]. Lesions
of the ventromedial nuclei may lead to disinhibited or
increased vagal tone resulting in hyperinsulinemia.
In fact, patients have an increased insulin secretion
compared with BMI-matched controls and the circulat-
ing insulin levels increase with developing peripheral
resistance to insulin action [27].
In 2009 Trivin et al evaluated the pre-surgery relation-
ship between the degree of the hypothalamic involve-
ment of craniopharyngioma patients on magnetic
resonance imaging and insulin resistance, as evaluated
by the homeostasis model insulin resistance index
(HOMA). Despite having similar BMI, patients with
severe hypothalamic involvement had higher glucose,
insulin and HOMA before surgery than patients without
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compression [28]. Moreover, the successful results of a
pharmacological trial have been considered an indirect
proof of role of insulin hypersecretion due to b-cell dys-
function in hypothalamic obesity [29]. In this trial, 18
obese subjects, with a previous history of childhood cra-
niopharyngioma received octreotide or placebo for 6
months. Treated patients experienced improved insulin
response to glucose, weight loss or lack of weight gain,
appetite suppression and reduced energy intake,
increased reported physical activity and decreased leptin
levels.
Furthermore, in craniopharyngioma survivors it has
been identified a difference in insulin sensitivity that
was found lower if analyzed by Frequently Sampled
Intravenous Glucose Tolerance Test (FSIGT) rather
than by Oral Glucose Tolerance Test (OGTT) [27]. This
different response may indicate the mediation of factors
such as autonomic innervation and gastrointestinal tract
hormones in the pathogenetic process. For instance, the
insulin secretagogue glucagon-like peptide 1 (GLP-1) is
released from the enteroendocrine L cells in the distal
intestine in response to glucose ingestion and leads to
enhanced insulin secretion. Exaggerated GLP-1 secretion
in response to an oral glucose load in individuals treated
for craniopharyngioma might link the findings of insulin
secretion and autonomic dysregulation. These are preco-
cious data and further studies are required to investigate
the hypothesis.
G h r e l i ni sah o r m o n ep r o d u c e dm a i n l yb yP / D 1c e l l s
lining the fundus of the human stomach and epsilon
cells of the pancreas [30]. It increases food intake and
fat mass by an action exerted at the level of the ARC
stimulating the orexigenic NPY neurons. The hyperghre-
linemia observed in Prader-Willi Syndrome has encour-
aged investigation into whether elevated ghrelin levels
are also present in hypothalamic obesity due to acquired
structural damage, as in craniopharyngioma. Neverthe-
less, data supporting a role for hyperghrelinemia in the
pathogenesis of hypothalamic obesity are still lacking
[7,31]. Goldstone et al found that fasting plasma ghrelin
in obese patients with craniopharyngioma was signifi-
cantly lower than that of patients with Prader-Willi Syn-
drome and did not differ from levels found in control
patients with common obesity [32]. Likewise, Kanuma-
kala et al found no difference in fasting total ghrelin
levels between patients with hypothalamic obesity and
controls with common diet- induced obesity [33].
Recently, the dynamic response of ghrelin to oral glu-
cose tolerance test was studied in 15 patients with
hypothalamic obesity and craniopharyngioma and in 15
BMI-matched controls. From 0-30 minutes after stimu-
lation, ghrelin decreased and insulin increased more in
patients compared with controls. This delayed ghrelin
suppression may contribute to obesity in obese cranio-
pharyngioma patients, but further studies are necessary
to better understand the meaning of this finding [34].
Lifestyle
Even if impaired satiety and hyperphagia, caused by dis-
ruption of the hypothalamic nuclei, have a central role
in the onset of hypothalamic obesity, reduced physical
activity, rather than increased total energy intake, was
found to be a major etiologic factor in the development
of obesity in survivors of childhood craniopharyngioma
[31]. Supporting data derived from the study of Harz
and colleagues. In fact, they demonstrated that the calo-
ric intake of patients with hypothalamic obesity from
craniopharyngioma, when determined by a validated
food diary, did not exceed that of control patients with
common obesity, but their movement activity, assessed
by accelerometer, was reduced both in the ambulatory
setting and in a clinically monitored weight loss envir-
onment [35]. Moreover, Müller in 2002 reported an
increased daytime sleepiness and reduced nocturnal
melatonin levels in patients with childhood craniophar-
yngioma supporting the hypothesis that in these patients
physical activity might be decreased due to as yet
unknown neuroendocrine disorders [36]. There are sev-
eral conditions may responsible of the reduction of
energy expenditure in these patients. Hypopituitarism
has to be considered one of these causes. Furthermore,
the tumor or its treatment may result in specific neuro-
logical or behavioral problems affecting physical activity
[37]. Functional capacity and its relation with weight
gain have been evaluated in 212 patients with childhood
craniopharyngioma. Patients with hypothalamic involve-
ment presented higher BMI SDS at the time of diagnosis
and at latest follow-up evaluation and lower functional
capacity when compared with patients without hypotha-
lamic involvement [17].
Treatment modalities
Any form of hypothalamic damage, whether due to
tumor, surgery or radiotherapy, is a regional-specific pri-
mary risk factor for the development of obesity. In a
longitudinal retrospective BMI-analysis (6.2 years post-
diagnosis) in 90 childhood craniopharyngioma patients,
survivors with hypothalamic involvement had higher
BMI at time of diagnosis and at annual follow-up inter-
vals [9]. At latest follow-up, BMI SD was 5.1 in survi-
vors with hypothalamic involvement versus 0.4 in those
without hypothalamic involvement. Only 10% of survi-
vors with hypothalamic involvement preserved normal
weight (versus 69% of survivors without hypothalamic
involvement), independent of the type of treatment. A
progression of the hypothalamus damage, determined by
different modalities of treatment, could deteriorate the
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aggressive surgical intervention [13], a lower rate of
gross total tumor resection during surgery [9] and mul-
tiple operations due to tumor recurrence [37] could
worsen the degree of obesity [38]. In addition, in an ele-
gant study of 148 survivors of childhood brain tumors,
Lustig sustained that survivors who received cranial
radiotherapy ≥ 51 Gy, especially if administered
hypothalamic, had greater BMI increase compared to
those who received less [18]. The multicenter Childhood
Cancer Survivor Study (CCSS) showed that treatment
with surgery and radiotherapy increased the risk of obe-
sity in female survivors about 3-fold compared with sur-
gery alone and documented the presence of a dose-
response relation between hypothalamic radiation and
obesity among females [39].
In craniopharyngioma, high-dose glucocorticoid treat-
ment is usually proposed at presentation with the aim
to ameliorate the symptoms of raised intracranial pres-
sure or after surgery to limit the postoperative edema.
In 2003 a retrospective analysis of 60 patients with
childhood craniopharyngioma inquired whether dose
and duration of perioperative dexamethasone therapy
had influence on short-term post-operative weight gain
and long-term development of severe obesity. Whereas
cumulative dexamethasone doses positively correlated
with weight gain during the first year following surgery,
long-term development of severe obesity was not influ-
enced by dose and duration of perioperative dexametha-
sone treatment [40].
Hypopituitarism
The geography of the tumors as well as surgery and
radiotherapy cause multiple pituitary hormone deficien-
cies. At diagnosis 71% of patients with craniopharyn-
gioma have symptoms suggesting the presence of an
endocrinopathy. Among them, 15% presented rapid and
excessive weight gain. After a mean of 7 years from the
initial surgery, multiple endocrinopathies are almost uni-
versal and 75% of children have panhypopituitarism
[41]. Several hormone deficiencies could contribute to
excess weight gain [18]. Although the adverse effects of
radiotherapy are dependent on dose, fractionation, age
at irradiation, time from irradiation and site, there is
evidence that growth hormone (GH) is the most sensi-
tive to these effects [42]. The irradiation of the hypotha-
l a m i c - p i t u i t a r ya x i sw i t h3 0G r a y( G y )o rm o r ei n
fractions provoke growth hormone deficiency (GHD)
with a risk of 60-100% within 2-5 years [43].
Evidences relate GHD to abnormal body composition,
including decreased lean body mass and an increased per-
centage of body fat, especially around the waist, and to
abnormal lipoprotein metabolism, increased peripheral
insulin resistance and impaired glucose tolerance [44-46].
Moreover children who undergo cranial radiation treat-
ment for brain cancer are at increased risk for other endo-
crine abnormalities, such as hypothyroidism [47],
precocious puberty or hypogonadism. After 5 or more
years from diagnosis, in CCSS-study one or more endo-
crine conditions were reported by 43% of childhood brain
tumor survivors. Compared with siblings, survivors had a
significantly increased risk of late-onset hypothyroidism
[relative risk (RR) = 14.3], of growth hormone deficiency
(RR = 277.8) and of the need for medications inducing
puberty (RR = 86.1) [48]. Very few late effects were evident
among those treated with surgery only, but risks were con-
sistently elevated for those treated with radiation and sur-
gery and higher for those who also received adjuvant
chemotherapy [48]. It is useless to remember than typical
symptoms of hypothyroidism are weariness and weight
gain. Hypocortisolism resulting from insufficient substitu-
tion of the hypothalamic-pituitary-adrenal axis reduces
physical activity. Overdosing with hydrocortisone, low
levels of testosterone and low levels of GH are all asso-
ciated with fatigue, a condition that, when chronic, can
lead to obesity. Moreover, also precocious puberty could
alter fat deposition, especially in girls.
Other risk factors
Another risk factor for BMI increase is younger age at
diagnosis [18]. Some biological reasons can explain this
finding. They include the continued brain growth and
mielinization until 4 years of age and the increased vulner-
ability of the developing brain to ionizing radiation. The
CCSS-study in 921 brain tumor survivors found that
female brain tumor survivors had a 3-fold increased risk
for being obese if the age at diagnosis was 9 years or less
compared with those diagnosed at older ages [39]. Data on
the role of the hydrocephalus requiring ventriculoperito-
neal shunt placement in weight gain are still conflicting
[18]. A low ponderal index at birth, suggestive of intrauter-
ine growth retardation, together with a maternal BMI
greater than 25 kg/m
2 have to be considered as other risk
factors for the development of obesity in craniopharyn-
gioma patients as well as in common obesity [9].
Metabolic consequences
An increased risk of cardio- and cerebrovascular mortal-
ity was observed in a study of 60 patients treated for
craniopharyngioma compared to the general population
during a median follow-up time of 12 years [49]. All the
factors identified as causes of developing hypothalamic
obesity, especially hypopituitarism and radiotherapy can
be interpreted as risk factors for cardiovascular disease
(CVD) later in life. Nevertheless, there is only limited
data on the development of CVD in long term survivors
of childhood central nervous system (CNS) cancer. It
has already been demonstrated convincingly that adult
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retrospective study of patients with hypopituitarism, the
risk of cardiovascular mortality was twice than in age-
and gender-matched healthy controls. In long-term sur-
vivors of childhood CNS tumors (70% cases of medullo-
blastoma) who received cranial irradiation exceeding 45
Gy, Heikens et al described an altered risk profile for
CVD with evidence of elevated systolic blood pressure,
increased waist-hip ratio and adverse lipid profile [52].
Moreover, patients with GHD due to cranial irradiation
presented a more pronounced altered metabolic profile
as well as an increased intima-media thickness (IMT) of
the carotid artery bulb [52]. The abnormalities were par-
ticularly pronounced in untreated GHD patients [53,54].
Srinivasan and colleagues were the first authors docu-
menting an increased risk of metabolic syndrome (MS)
in children with GHD and hypothalamic obesity after
craniopharyngioma surgery. In fact, 9 patients post-cra-
niopharyngioma surgery presented a higher fasting level
of triglycerides and a lower high density lipoprotein cho-
lesterol to total cholesterol ratio compared to those of
healthy age-, sex-, pubertal stage- and BMI-matched
controls [19]. Recently, after 4.9 ± 3.0 years from the
diagnosis of craniopharyngioma, MS was detected in
73.3% (10/15) of survivors and in 20% (3/15) of age-,
gender-, pubertal stage- and BMI-matched controls [27].
Moreover, children and adolescents with hypothalamic
obesity following craniopharyngioma resection exhibited
significantly more features of MS compared controls if
they had a greater degree of impaired glucose tolerance,
higher TNF-alpha and free fatty acids levels. All of these
factors are known to contribute to increased cardiovas-
cular risk in adults.
Conclusion
The comprehension of the natural history and aetiology
of obesity in craniopharyngioma survivors as well as the
identification of modifiable risk factors should facilitate
preventive interventions in the future. In fact, the man-
agement of obesity and eating disorders remains diffi-
cult, especially in patients with hypothalamic lesions.
Nowadays, the best recommendation is the early begin-
ning of prophylactic and therapeutic interventions in
patients at risk of obesity. They should focus on promo-
tion of a reduction in sedentary behavior and increases
in physical activity. The American Cancer Society has
developed specific guidelines on diet, nutrition and can-
cer prevention for the maintenance of health in the gen-
eral population as well as in survivors of cancer [55].
The suggested diet is characterized by five or more ser-
vings of fruits and vegetables per day, the choice of
whole grain foods and a limited amount of red meat,
foods high in fat content and alcoholic beverages. In
addition, 30-60 minutes of moderate to vigorous
exercise at least or more than five times per week
should be performed. Such interventions should be
helpful in obesity prevention, but could also have a wide
range of additional benefits in the prevention or ameli-
oration of other late effects of cancer treatment. A mul-
tidisciplinary approach has to be offered to patients
soon after the diagnosis of childhood cancer, continue
through long-term follow up and extent into adulthood.
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